Latanoprost and clinically significant cystoid macular edema after uneventful phacoemulsification with intraocular lens implantation

Journal of Cataract and Refractive Surgery

Volumn 28, Issue 10, 2002, Pages 1814-1818

  Yeh, Patrick C ^a   Ramanathan, Saras ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAXOLOL; BRIMONIDINE; DEXAMETHASONE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; KETOROLAC; LATANOPROST; OFLOXACIN; PILOCARPINE; PREDNISOLONE ACETATE; TIMOLOL MALEATE; TOBRAMYCIN;

ARTICLE; CATARACT EXTRACTION; EFFUSION; EYE INFLAMMATION; FISHER EXACT TEST; GLAUCOMA; HUMAN; HYPERTRICHOSIS; IRIDOCYCLITIS; IRITIS; LENS IMPLANTATION; MAJOR CLINICAL STUDY; OPHTHALMOSCOPY; PHACOEMULSIFICATION; PIGMENT DISORDER; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; VISUAL ACUITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; KETOROLAC; LENS IMPLANTATION, INTRAOCULAR; MACULAR EDEMA, CYSTOID; PHACOEMULSIFICATION; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES;

EID: 0036799527     PISSN: 08863350     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0886-3350(02)01334-2     Document Type: Article

References (38)

1. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993; 100:1297-1304
2. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997; 41(suppl 2): S105-S110
3. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997; 41(suppl 2):S129-S138
4. Watson PG. Latanoprost; two years' experience of its use in the United Kingdom; the Latanoprost Study Group. Ophthalmology 1998; 105:82-87; discussion by JA Alvarado, 87
5. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy; efficacy and safety after 1 year of treatment in 198 patients; the Latanoprost Study Group. Ophthalmology 1996; 103:1916-1924
6. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997; 115:1206-1209
7. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124:544-547
8. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use; experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998; 105:263-268
9. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126:37-41
10. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol 1997; 124:683-685
11. Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol 1998; 116:679-680
12. Heier JS, Steinert RF, Frederick AR Jr. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol 1998; 116:680-682
13. Gaddie IB, Bennett DW. Cystoid macular edema associated with the use of latanoprost. J Am Optom Assoc 1998; 69:122-128
14. Wardrop DRA, Wishart PK. Latanoprost and cystoid macular oedema in a pseudophake. (letter) Br J Ophthalmol 1998; 82:843-844
15. Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999; 106:1024-1029
16. 2α-1-isopropyl ester. Exp Eye Res 1987; 44:217-226
17. Schoenwald RD, Deshpande GS, Rethwisch DG, Barfknecht CF. Penetration into the anterior chamber via the conjunctival/scleral pathway. J Ocul Pharmacol Ther 1997; 13:41-59
18. Green K, Bowman K, Luxenberg MN, Friberg TR. Penetration of topical indomethacin into phakic and aphakic rabbit eyes. Arch Ophthalmol 1983; 101:284-288
19. Chen CC, Anderson J, Shackleton M, Attard J. The disposition of bunolol in the rabbit eye. J Ocul Pharmacol 1987; 3:149-157
20. Acheampong AA, Breau A, Shackleton M, et al. Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbits. J Ocul Pharmacol Ther 1995; 11:489-502
21. Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol 1997; 41(suppl 2):S69-S75
22. Kosaka T. [The effects of long term topically applied prostaglandins on aqueous protein concentration and the rabbit ciliary process]. [Japanese] Nippon Ganka Gakkai Zasshi 1994; 98:435-442
23. Kosaka T. The effects of prostaglandins on the blood-retinal barrier. Nippon Ganka Gakkai Zasshi 1995; 99: 412-419
24. Hoyng PFJ, Rulo AH, Greve EL, et al. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: A review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol 1997; 41 (suppl 2):S83-S88
25. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993; 111:1351-1358
26. 2α-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol 1993; 37:259-269
27. Miyake K, Ota I, Maekubo K, et al. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol 1999; 117:34-40
28. Halperin LS, Goldman HB. Cystoid macular edema associated with topical echthiophate iodide. Ann Ophthalmol 1993; 25:457-458
29. Irvine SR. A newly defined vitreous syndrome following cataract surgery; interpreted according to recent concepts of the structure of the vitreous. Am J Ophthalmol 1953; 36:599-619
30. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 1998; 96:557-634
31. Miyake K, Sugiyama S, Norimatsu I, Ozawa T. Aqueous prostaglandins in persistent cystoid macular edema secondary to vitreous incarceration: Effects of pars plana vitrectomy. Jpn J Ophthalmol 1980; 24:335-345
32. Miyake K, Sugiyama S, Norimatsu I, Ozawa T. Prevention of cystoid macular edema after lens extraction by topical indomethacin (III). Radioimmunoassay measurement of prostaglandins in the aqueous during and after lens extraction procedures. Albrecht von Graefes Arch Klin Exp Ophthalmol 1978; 209:83-88
33. Neufeld AH, Jampol LM, Sears ML. Aspirin prevents the disruption of the blood-aqueous barrier in the rabbit eye. Nature 1972; 238:158-159
34. Peyman GA, Bennett TO, Vlchek J. Effects of intravitreal prostaglandins on retinal vasculature. Ann Ophthalmol 1975; 7:279-288
35. Tsukahara S, Kohda N. [The effects of prostaglandins on the blood-ocular barrier: II. Blood-retinal barrier]. [Japanese] Acta Soc Ophthalmol Jpn 1977; 81:193-198
36. Podos SM. Prostaglandins, nonsteroidal anti-inflammatory agents and eye disease. Trans Am Ophthalmol Soc 1976; 74:637-660
37. Jahn CE. Reduced intraocular pressure after phacoemulsification and posterior chamber intraocular lens implantation. J Cataract Refract Surg 1997; 23:1260-1264
38. Link S, Haring G, Hedderich J. Einfluss der phakoemulsifikation und implantation auf den intraokulardruck bei patienten mit und ohne offenwinkelglaukom. Ophthalmologe 2000; 97:402-406